Zacks.com on MSN2d
Monte Rosa Therapeutics (GLUE) Q4 Earnings and Revenues Top EstimatesMonte Rosa Therapeutics (GLUE) delivered earnings and revenue surprises of 162.16% and 374.06%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback